Fredun Pharmaceuticals Share Price Today

Fredun Pharmaceuticals plans shift to fully branded portfolio by 2029

Fredun Pharmaceuticals is transforming into a high-growth branded healthcare platform. The company plans to transition to a 100% branded portfolio by 2029. Strategic investments are being made in the pet-care ecosystem. Capacity expansion is underway to support growth objectives. The company targets doubling of revenue and profitability over the next 3-4 years.

Fredun Pharma acquires 26% stake in Goodman Vetcare for ₹300 crore

Fredun Pharmaceuticals acquires 26% stake in Goodman Vetcare, valuing the chain at ₹300 crore. Goodman Vetcare targets ₹40 crore revenue by FY27 and ₹56 crore by FY28. The pet-care retailer aims to reach nearly ₹100 crore in revenue by FY31. Goodman plans to open eight new stores across three cities with breakeven within 3-4 months.

Fredun Pharmaceuticals expands Furlicks pet brand to 22 SKUs

Fredun Pharmaceuticals expands Furlicks from 6 to 22 SKUs. Plans to launch 16 new products in 6-9 months. New formats include freeze-dried and functional biscuits. Brand acquired from USV and Wellbeing Nutrition.

Fredun Pharmaceuticals shares permitted to trade on NSE from August 17

Fredun Pharmaceuticals Limited has secured permission from the National Stock Exchange of India Limited to commence trading of its equity shares starting August 17, 2026. The listing expands the company's market presence alongside its existing BSE listing. Shares will trade under the symbol FREDUN with a face value of ₹10.

Fredun Pharmaceuticals Q1 Results: Net profit up 94.63% YoY to ₹13.17 crore

Fredun Pharmaceuticals reported Q1 FY27 standalone total income of ₹228.25 crore, up 90.44% YoY, with net profit rising 94.63% YoY to ₹13.17 crore. EBITDA grew 92.90% YoY to ₹32.78 crore, with EBITDA margin expanding 18 bps to 14.36% and net profit margin improving 12 bps to 5.77%. Management guided for FY27 revenue of approximately ₹800 crore and outlined CapEx of ₹30 crore to ₹40 crore for the year, alongside 40% to 50% growth targets in pet care and 25% to 35% growth in the GX segment.

Fredun Pharmaceuticals Q1 Results: Earnings call scheduled for Aug 13, 2026

Fredun Pharmaceuticals Limited has scheduled its Q1 FY27 Earnings Conference Call for Thursday, 13th August, 2026 at 11:30 AM IST. The call, hosted in association with Kirin Advisors, will feature Managing Director Mr. Fredun Medhora as the speaker from management. Participants can join via dial-in numbers +91 22 6280 1239 or +91 22 7115 8140, or register online through the Diamond Pass Login link. The announcement was filed with BSE Limited on 8th August, 2026.